ThePeptideGuide.uk LogoNavigation

Educational purposes only. Not medical advice. Consult healthcare professionals before use.

Healing & Recovery
Phase 3

ARA-290

ARA-290

Also known as: Cibinetide, Helix B Surface Peptide, HBSP

Overview

Key Facts

Primary Goal: An 11-amino acid synthetic peptide derived from the B helix of erythropoietin

An 11-amino acid synthetic peptide derived from the B helix of erythropoietin. Selectively activates the innate repair receptor (IRR) to promote tissue protection and repair without erythropoietic (blood cell) stimulation. Half-Life ~2 minutes (rapid clearance, prolonged tissue effects) Typical Dose 2–4 mg Frequency 1x daily Cycle Length 4-12 weeks

Dosing Information

Half-Life

~2 minutes (rapid clearance, prolonged tissue effects)

Typical Dose

2–4 mg

Frequency

1x daily

Cycle Length

4-12 weeks

Administration Routes:

subcutaneousintravenous

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F) or -20°C (-4°F) for long-term
DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)
Duration1 week

Research Summary

Phase 3

Multiple Phase 2 clinical trials completed for sarcoidosis-associated neuropathy and diabetic neuropathic pain. Demonstrated improved corneal nerve fiber density and reduced neuropathic symptoms. Developed by Araim Pharmaceuticals with promising safety and tolerability data.

Frequently Asked Questions

Common questions about ARA-290

UK-Specific Information

Exclusive data points and guidance for UK residents using ARA-290

UK Lab Testing

US Lab Testing

Recommended labs: Quest Diagnostics, LabCorp ($120-$200 for peptide safety panel)

Why this matters: UK-specific lab testing guidance not available on US competitor sites

Commonly Stacked With